Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

446
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
446
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

256
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.

Rheumatology and therapy·2026
Same author

Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study.

Rheumatology and therapy·2025
Same author

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Rheumatology and therapy·2025
Same author

Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe.

Rheumatology and therapy·2025
Same author

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials.

Rheumatology and therapy·2025
Same author

Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study.

Arthritis research & therapy·2025

Related Experiment Video

Updated: Aug 28, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.3K

Emerging injectable therapies for osteoarthritis.

Julia Sewell1, Andrew Östör2

  • 1Rheumatology Department, Monash Health, Melbourne, Australia.

Expert Opinion on Emerging Drugs
|September 14, 2022
PubMed
Summary

Osteoarthritis (OA) is a serious disease impacting millions globally. Emerging therapies target novel pathways, prompting a reevaluation of current OA treatment strategies beyond cartilage degeneration.

Keywords:
Analgesiacytokinedisease-modifying osteoarthritis drughipinflammationinjectableinterleukinkneematrix extracellular phosphoglycoproteinsosteoarthritis

More Related Videos

Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers
09:02

Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers

Published on: August 10, 2020

7.6K
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

5.1K

Related Experiment Videos

Last Updated: Aug 28, 2025

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.3K
Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers
09:02

Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers

Published on: August 10, 2020

7.6K
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

5.1K

Area of Science:

  • Rheumatology and Orthopedics
  • Pharmacology
  • Regenerative Medicine

Background:

  • Osteoarthritis (OA) affects over 240 million people worldwide, recognized as a serious condition with significant unmet needs.
  • Current international OA treatment guidelines have remained largely unchanged for over a decade.
  • OA is now understood as more than just articular cartilage 'wear-and-tear', involving complex inflammatory and pain pathways.

Approach:

  • Review of emerging therapeutic strategies targeting novel inflammatory, pain, and regeneration pathways in OA.
  • Exploration of the concept of 'Disease-Modifying Osteoarthritis Drugs' (DMOADs) and the challenges in their development.
  • Consideration of the impact of the global pandemic on OA management and the need for non-surgical treatment options.

Key Points:

  • Emerging therapies aim to address OA through innovative approaches beyond traditional management.
  • The development of DMOADs remains a critical, yet elusive, goal in OA research.
  • The pandemic highlights the need for expanded pharmacological options to manage OA without hospitalization.

Conclusions:

  • This review advocates for a paradigm shift in thinking about OA treatment, despite not recommending immediate changes to current practice.
  • A broader pharmacological armamentarium is needed to manage OA effectively, especially in light of strained healthcare systems.
  • Rethinking the OA treatment paradigm is crucial for addressing the disease comprehensively and adapting to global health challenges.